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Lithium treatment reduces the renal kalHkrein excretion rate. Lithium 
salts are widely used agents for the prophylactic treatment of affective 
disorders. Lithium salts may be associated with distal nephron dysfunc-
tion. Kallikrein is a protease which is generated by the distal nephron. 
We used an amidolytic assay of chromatographically purified enzyme to 
determine the urinary excretion rate of active kallikrein in relation to 
lithium treatment. All plasma lithium concentrations were within the 
therapeutic range (0.4 to 0.9 mmol/liter). In 15 patients the urinary 
excretion rate of active kallikrein was 267.4 ± 65.6 mU/24 hrs before 
lithium treatment, and fell to 117.8 ± 39.6 mU/24 hrs (P < 0.05) on day 
14 of lithium treatment. This reduction was associated with a decrease 
of immunoreactive kallikrein in the same urines by 66%. In another 15 
patients who had undergone lithium therapy for an average period of 5.6 
years, the urinary excretion rate of active kallikrein was 86.1 ± 14.5 
mU/24 hrs, while 21 age-matched healthy controls had an excretion rate 
of 364.1 ± 58.4 m U/24 hrs (P < 0.05). Measurements of immunoreac-
tive kallikrein in the same urine sampIes demonstrated a reduction of 
kallikrein after long-term lithium treatment by 78%. These observations 
could not be attributed to changes in creatinine cIearance, renal sodium 
or potassium excretion rates or plasma concentrations of aldosterone 
and vasopressin. Addition of lithium to the urine in vitro had no 
demonstrable effect on kallikrein measurement by amidolytic assay. We 
concIude that lithium in therapeutic plasma concentrations may directly 
suppress the secretion of kallikrein by renal connecting tubule cells. 
The effectiveness of lithium as a prophylactic treatment of 
affective disorders is well established [1]. The large number of 
patients affiicted and the necessity to prescribe lithium treat-
ment over prolonged periods-often involving many years [1, 
2]-has raised concern about potential side-effects of this 
medication [3]. In the kidney adverse effects may occur at 
therapeutic plasma levels of lithium. They inelude nephrogenic 
diabetes insipidus [4], defective distal tubular acidification [5] 
and others [3]. In addition, renal morphological changes have 
been observed in distal tubular, connecting tubular and collect-
ing duct epithelia [6-12]. Taken together, these observations 
indicate a preferential involvement of the distal nephron in 
those adverse effects. 
Kallikrein is an enzyme which may generate kinins [13]. In 
the kidney kallikrein is produced and released by connecting 
tubular epithelial cells of the distal nephron [13-16]. We were 
intrigued by the elose spatial relationship between the site of 
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kallikrein release and the localization of functional and morpho-
logical changes observed after lithium in the kidney. We asked 
the question whether lithium treatment might also affect renal 
kallikrein. 
Methods 
Patients 
To test the effects of short-term and long-term lithium treat-
ment the urinary excretion rate of kallikrein was measured in 
several groups of patients: 
a) In 15 patients suffering from a DSM-III affective disorder 
(manie depressive disorder) [171. who had never received lith-
ium before. They were consecutive admissions to the Depart-
ment of Psychiatry of the University of Heidelberg. Measure-
ments were obtained just prior to the beginning of lithium 
therapy and then again on day 14 of such treatment. 
b) In 15 randomly-selected patients who had previously 
received continuous lithium treatment of an affective disorder 
for at least one year. All of these patients were cared for by the 
out-patient elinic of the Department of Psychiatry of the Uni-
versity of Heidelberg. 
c) Measurements were simultaneously obtained in 21 age-
matched healthy volunteers serving as controls. A plasma 
lithium concentration of 0.4 to 0.9 mm01l1iter is considered 
therapeutic at our institution; patients included in our study did 
not exceed this range of concentrations. In all instances lithium 
therapy had been recommended by the psychiatrists in charge 
of the patient. All patients had given prior consent to the 
procedures of the study. 
Protocol of evaluation 
When a patient was entered into the study, we obtained a 
his tory , a complete physical examination and a standardized 
blood sampie at rest. We documented the present symptoms, 
the indications for lithium treatment, the current medication 
and any historical evidence of recent dehydration. In the 
physical examination, we searched for signs of dehydration or 
plasma volume contraction. All blood sampIes were drawn at 
about 3 p.m.; patients were not fasting. After placement of a 
short indwelling catheter into a forearm vein, the patient rested 
supine for 40 minutes. A 14 ce blood sampIe was drawn, 
immediately partitioned into the appropriate iced tubes, placed 
on ice and rapidly centrifuged at 3°C, at 4,800 x g for 10 
minutes. The following parameters were measured: electrolytes 
ineluding lithium, magnesium and calcium; creatinine, urea and 
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urate; total protein and albumin; osmolality; plasma renin 
activity (PRA); aldosterone and antidiuretic hormone (ADH). 
Urine sampies . All measurements were based on the consec-
utive collection of two 24-hour urine specimens. These speci-
mens were pooled and submitted for measurements thereafter. 
Specific precautions were taken to ensure completeness of 
colJection. While the collection was in progress, urine sampies 
were kept in a refrigerator at 3°C. The folJowing parameters 
were determined: urinary volume; osmolality; creatinine c1ear-
ance; electrolytes including magnesium and phosphate; the 
kallikrein excretion rate was determined by amidolytic assay 
and by radioimmunoassay (RIA). 
Laboratory procedures 
Osmolality (normal range: 280 to 300 mOsm/kg H20) was 
measured by freezing point depression on an Osmomat 030 
(Gonotec GmbH, Berlin, FRG) as described [18]; sodium, 
potassium and lithium concentrations (recommended range of 
lithium: 0.4 to 0.9 mmol/liter) were determined by flame pho-
tometry (Beckman Instruments , Munich, FRG); creatinine, 
urea (normal range: 15 to 45 mg/dl) , urate (normal range: 2.0 to 
7.0 mg/dl), calcium, albumin and total protein concentrations by 
autoanalyzer (Technicon, Dublin, Ireland, UK); magnesium 
concentration by atomic absorption spectrophotometry (Perkin 
Eimer, model 290, Überlingen, FRG). The plasma aldosterone 
concentration (normal range: 2.0 to 10.0 ng/dl) was determined 
by RIA [19]; PRA by the method of Haber et al with minor 
modifications (range of normal results at rest: 0.3 to 2.0 ng 
AI/mi x hr) [20]; ADH by RIA as described [21] (the mean 
plasma ADH concentration in 20 adult volunteers by this assay 
was 2.9 ± 1.0 pg/ml). 
Specijic measurements 
The amidolytic assay of kallikrein was based on previously 
described methods [22-27]. In short , aliquots of thawed urine 
were dialyzed against distilled water for 24 hours. This was 
folJowed by dialysis against a phosphate-buffered (10 mM, pH 
7.0) KCI solution for an additional 24 hours. Dialyzed urine 
sampies were passed through columns containing DEAE-
SEPHADEX A-50 (Pharmacia Fine Chemicals, Freiburg, 
FRG), 4 cc per column. Kallikrein was eluted with phosphate-
buffered KCI solution (700 mM of KCl) after rinsing with 200 
mM KCI. No correction was made for losses. Amidolytic 
activity was determined by incubating 400 J.d of eluate with 0.15 
mM D-VAL-LEU-ARG-PARANITROANILIDE (S 2266, Kabi 
Diagnostica GmbH, Munich, FRG) and 5oo,uI ofTRIS-HCI (pH 
8.2; 0.2 mol/liter). Incubation was maintained for 30 minutes at 
37°C, after which the reaction was stopped by addition of loo,ul 
of 50% acetic acid. The enzymatic c1eavage of S 2266, yielding 
p-nitroaniline, attributable to the enzymatic activity of kal-
likrein was measured photometrically (Perkin Eimer 550 A, Oak 
Brook, Illinois, USA) at 405 nm against a blank. Results of 
measurements are reported in units (U) ; one unit is the amount 
of enzyme capable of c1eaving one ,umol of S 2266 per minute at 
37°C. The range of normal values for urinary kallikrein deter-
mined by this assay is reported by our laboratory as 310 to 420 
mU/24 hrs. 
Table 1. Measurements of plasma and urinary parameters before and 
after 14 days of lithium therapy in 15 patients with manie depressive 
disorder (DSM-IlI affective disorder) 
After 14 
Before days of 
Parameter lithium lithium P 
Measurements in plasma 
Lithium concentration 0.81 ± 0.01 
mMlliter 
Urea concentration 29.0 ± 2.4 30.0 ± 1.8 NS 
mg/dl 
Urate concentration 4.6 ± 0.2 4.8 ± 0.3 NS 
mg/dl 
Osmolality mOsm/kg 293.0 ± 1.0 293.0 ± 1.1 NS 
Aldosterone ng/dl 10.0 ± 1.3 9.1 ± 2 NS 
PRA ng AI/mi x hr 0.85 ± 0.1 0.96 ± 0.2 NS 
ADH pg/ml 2.2 ± 0.26 2.6 ± 0.47 NS 
Measurements in urine 
Urinary volume 1/24 hr 1.9 ± 0.2 1.8 ± 0.2 NS 
Clearance of creatinine 99.7 ± 5.0 100 ± 6.9 NS 
mllminlI.73 nr 
Sodium excretion rate 169 ± 22 162 ± 19.9 NS 
mM/24 hrs 
Potassium excretion rate 70 ± 4.2 81 ± 11.1 NS 
mM/24 hrs 
The following parameters were also measured, but remained normal 
and unaltered: a) plasma concentrations of sodium, potassium, calcium, 
phosphate, magnesium, albumin and total protein; b) urinary excretion 
rates of phosphate and osmoles. 
Radioimmunoassay 0/ kallikrein 
The method used has been described in detail [28]. In the 
assay an antibody against kallikrein raised in rabbits was used. 
The lower limit of detection of kallikrein by this assay is 0.5 
,uglliter. The range of normal values of kallikrein measured by 
this assay is reported by our laboratory as 60 to 100 ,ug/24 hrs. 
For measurements of kallikrein by RIA, which will be re-
ported in the subsequent section on resuIts, we routinely 
employed the same pretreatment of urine sampies as described 
above for amidolytic assay. However, in a sub set of 12, 
randomIy-selected urine specimens, we also compared results 
obtained by amidolytic assay as described above with those by 
radioimmunoassay without urinary pretreatment. A significant 
correlation of both measurements was found (N = 12; r = 0.89; 
P < O.OOO}). 
Statistics 
Results of measurements are reported as mean values ± SEM. 
The Wilcoxon signed rank test was used for comparison be-
tween groups of data. 
Results 
General observations in short-term lithium treatment 
In all 15 patients (women: 9, men: 6; mean age 39 years, range 
18 to 67) a diagnosis ofDSM-III affective disorder [17] had been 
established. During the first 14 days of treatment plasma 
concentrations of lithium were within the therapeutic range 
«0.9 mM; Table l). Lithium therapy was associated with 
transient diarrhea (2 patients) and increased thirst in one 
patient. The dosages of additional psychiatrie medications 
remained unaltered throughout the study. Patients did not show 
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Fig. 1. Urinary excretion rate 0/ active kallikrein during lithium treat-
ment and control as determined by amidolytic activity 0/ kallikrein. *p 
< 0.05 
physical signs of dehydration or extracellular fluid volume 
depletion. The body weight was 69.5 ± 3.3 kg before and 69.9 
± 4.1 kg on day 14 oflithium therapy (P = NS). Oral fluid intake 
was 2.5 ± 0.3 1/24 hrs before and 2.4 ± 0.3 1/24 hrs on day 14 
of lithium therapy (P = NS). Upright mean arterial blood 
pressure taken after three minutes of standing had a tendency to 
increase (baseline: 90 ± 4.5 mm Hg, day 14 of lithium therapy: 
94.4 ± 3.7 mm Hg), but the change was not significant (P < 
0.09). Table 1 shows parameters which document hydration, 
extracellular fluid volume status, creatinine clearance and po-
tential imbalances of renal electrolyte handling at the time of 
kallikrein measurement. Osmolar clearance was 2.2 ± 0.08 
mlfmin at baseline and 2.2 ± 0.09 on day 14 of lithium therapy 
(P = NS); free water clearance at baseline was -0.86 ± 0.07 
mlfmin, and on day 14 of lithium therapy was -0.97 ± 0.08 (P 
= NS). All of these data failed to demonstrate any abnormali-
ties or significant changes after the beginning of lithium treat-
ment. 
General observations in long-term lithium treatment 
The 15 patients (women: 6, men: 9; mean age 39 years, range 
14 to 66) underwent an abbreviated evaluation primarily to 
measure urinary kallikrein excretion. At the time of our study, 
the average duration of lithium treatment had been 5.6 years. 
Physical examination demonstrated normal hydration. The 24-
hour urinary volume was 2.1 ± 0.3 liter. The serum lithium 
concentration was 0.8 ± 0.08 mM/liter. Serum electrolytes and 
concentrations of urea and urate were all within normal limits; 
the plasma creatinine concentration was 0.99 ± 0.1 mg/dl, 
which was normal. Urinary protein excretion rate was less than 
200 mg/24 hrs in all. 
Kallikrein in 24-hour urine sampIes 
Short-term lithium treatment was associated with a signifi-
cant reduction of the excretion rate of active kallikrein (amido-
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Fig. 2. Urinary excretion rate o/immunoreactive kallikrein in response 
to lithium treatment and during control as determined by radioimmu-
noassay. *p< 0.05 
lytic assay) by 56% (Fig. 1). This reduction was apparent as 
early as 72 hours after the beginning of lithium treatment. Thus, 
four randomly selected patients who collected urine sampies at 
72 hours after the beginning of lithium treatment had a reduced 
excretion of active kallikrein of 117.4 ± 77.8 mU/24 hrs (data 
not shown in Fig. 1). Figure 1 also demonstrates comparable 
findings in 15 patients who had undergone long-term lithium 
treatment over several years. Results of measurements of 
immunoreactive kallikrein are shown in Figure 2. The measure-
ments were performed on eluates from the same 24-hour urine 
sam pies that had also been subjected to amidolytic assay 
yielding the results reported in Figure 1. The set of observations 
of active kallikrein (amidolytic assay, Fig. 1) closely resembled 
the set of observations of immunoreactive kallikrein (Fig. 2). 
When the results of both methods of measurement were ana-
lyzed by regression analysis they were significantly correlated 
(N = 66; r = 0.62; P < 0.00001). 
lnfluence 01 lithium on amidolytic assay 
Eight control urine sampies were selected at random and 
divided into two aliquots of equal volume. Lithium carbonate 
was added to each second aliquot yielding a final concentration 
of 5 mM/liter of lithium. Kallikrein activity was determined 
subsequently in all 16 sampies by a blinded observer. Kallikrein 
was 412 ± 9.1 mU in the eight sampies without lithium addition 
and 414 ± 10.4 (P = NS) after pretreatment by lithium. Thus, 
there was no difference between amidolytic measurements in 
the presence or absence of lithium in urine sampies. 
Discussion 
The urinary kallikrein excretion rate was found to be signif-
icantly reduced in association with lithium treatment. This 
finding was demonstrated by two different methods of assay for 
urinary kallikrein: the amidolytic assay of active kallikrein and 
the radioimmunoassay. No attempts were made to measure 
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inactive kallikrein by amidolytic assay after its activation. We 
were able to exclude an interference between lithium and the 
amidolytic assay. Reduced kallikrein excretion was consis-
tently present in different stages of lithium therapy. It could be 
documented as early as 72 hrs after the beginning of lithium 
therapy, as weH as after 14 days and several years of such 
therapy. Reduced kallikrein excretion occurred in patients that 
had plasma lithium concentrations within the therapeutic range. 
There was no evidence of renal insufficiency [29, 30] in these 
patients. No changes of ADH [31], aldosterone [32], or potas-
sium and sodium output [33-34] were found that might have 
contributed to the observed reduction of kallikrein excretion. 
Therefore, we propose that lithium per se causes reduced renal 
kallikrein excretion at low plasma concentrations. To our 
knowledge this has not been reported before. However, as 
documented in arecent preliminary report from our laboratory, 
it was possible to reproduce the same finding in experimental 
animals [35]. The latter observations indicated a reduced uri-
nary excretion rate of kallikrein along with a reduced renal 
cortical content of kallikrein during lithium treatment in the rat. 
Several renal side-effects of lithium have been reported. They 
are: nephrogenic diabetes insipidus [4, 9, 36], reduced glomer-
ular filtration rate [37-39], hypercalcemia [40] and increased 
excretion of sodium, potassium, calcium and phosphate by the 
kidney [41-43]. None ofthese adverse effects were noted in the 
patients of our study. Distal tubular acidification, which may 
also be impaired [5, 44, 45], was not tested. Thus, our findings 
do not clarify the relationship between the observed reduction 
of kallikrein and the development of adverse effects of lithium 
in the kidney. However, we were intrigued by findings in a 
single patient with lithium intoxication-not mentioned in the 
above-who had a plasma lithium concentration of 2.8 mM/liter, 
urinary kallikrein concentration too low to be detectable by our 
assay, and nonoliguric deterioration of renal function. 
In future studies, the establishment of a relationship between 
the plasma concentration of lithium and any renal side-effects of 
this medication might be attempted. Conceivably, there could 
be an order of increasing severity in renal side-effects, in which 
reduced excretion of kallikrein might be an early event. In 
addition, in such future studies, it mayaiso be worthwhile to 
test the effect of lithium-and thereby of reduced kallikrein-on 
renal perfusion. If a relationship of this kind existed, it might 
contribute to the understanding of renal lithium toxicity. 
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